

Investor Presentation – AngelMed Guardian FDA Approval

Hydrix Limited (ASX: **HYD**) attaches an investor presentation in relation to the recent FDA approval of the AngelMed Guardian device, as announced to the market on 28 June 2021.

A recorded presentation given by Executive Chairman Gavin Coote, which provides a narrative to the Investor Presentation slides, can be accessed at the following link: [Video link](#)

-ENDS-

Authorisation: This announcement has been authorised by the Board of Hydrix Limited.

Contact Details: For more information, please contact:

Media Enquiries:

Rod North

Managing Director, Bourse Communications

rod@boursecommunications.com.au

+61 3 9510 8309

About Hydrix Limited

Hydrix Limited (ASX: HYD) is a powerful product innovation company. Hydrix purpose is to enhance the health, safety, and wellbeing of one Billion lives. The company leverages its powerful product innovation capability across multiple growth platforms: Hydrix Services design and engineer client products which transform industries; Hydrix Ventures generate equity returns through investing in high potential companies; and Hydrix Medical bring innovative medical technologies to market.

Hydrix Limited

Hydrix brings technologies to life which improve people's health, safety and well-being

AngelMed FDA Approval ASX Announcement on 28 June

MedTech/Cardiac business poised for strong product revenue growth

- Diversified medtech product design services and distribution business – 18-year history, global customers
- “One stop Services shop” bringing medical technology concepts to commercialisation
- Exclusive APAC rights to distribute *world's first/only implantable heart attack alert device*
 - Commenced first in world commercial sales/implants in SNG August 2020 (*special access scheme*)
 - Announced US FDA Approval 28 June
 - Australia TGA and Singapore HSA approvals to come
- Positioned for high growth selling Cardiac devices in APAC beginning 2H FY22



Hydrix Medical – Portfolio overview

AngelMed Guardian




A 3%
capture rate
of patient
market =
\$100m rev
p.a. (15k
units)

Implanted Heart Monitor

- 3rd party distribution agreement (7 years +2 years).
- An implantable continuous heart monitoring device that detects Acute Coronary Syndrome (ACS) events, including silent heart attacks.
- A global 'first of kind' device, approved by the FDA who concluded the AngelMed Guardian "satisfies an unmet need."

Phyzhon



A 15%
capture rate
of PCI
surgery
market =
\$25m rev p.a.
(20k units)

Interventional cardiology device

- Exclusive rights to distribute in Australia & New Zealand.
- Single-use device for interventional cardiology surgery to manage coronary artery blockages.
- High potential to disrupt current products and procedures, improve patient and cardiologist outcomes, reduce operating time and lower hospital costs.



Indicative Milestone Timelines / Potential News Flow

1H FY22

- Submit TGA (AUS) and HSA (SNG) regulatory approval for AngelMed Guardian
- First implants of AngelMed Guardian in Australia under Special Access Scheme (SAS)
- Commence First in Human (FIH) Trials for Phyzhon in Melbourne, Australia
- Appoint APAC sub-distributors for AngelMed Guardian
- Potential Hydrix Ventures portfolio updates and revaluation events
- Ongoing evaluation of several high-growth potential “Buy, Build, Invest” initiatives

2H FY22

- AngelMed Guardian TGA (AUS) & HSA (SNG) regulatory approval
- AngelMed Guardian AUS health reimbursement approval
- Commence commercial sales of AngelMed in AUS, NZ & SNG
- CE Mark approval of Phyzhon
- Sales of Phyzhon under authorized prescriber scheme in Melbourne Australia
- TGA regulatory approval for Phyzhon once CE Mark approved
- Commence commercial sales of Phyzhon Guidewire in AUS & NZ



Disclaimer

This presentation has been prepared by Hydrix Limited (the “Company” or “Hydrix”). This presentation is being provided to investors for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business activities of the Company. The document is not intended to constitute an invitation or an inducement to engage in any investment activity. The presentation is not intended to constitute investment advice and should not be relied upon as such. This document is not intended as an offer or recommendation with respect to the purchase or sale of any securities in the Company.

The content and graphical illustrations contained in the presentation are provided for information purposes and should not be relied upon to form any investment decisions or to predict future performance. The Company is wholly reliant upon third parties for the accuracy and completeness of the information in the presentation and has no duty of care owed to you in relation to such information. Although the information expressed is provided in good faith and the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved. Important factors that could cause actual results to differ materially from those included in the forward-looking statements include amongst others, unforeseen delays in product development, the timing and extent of any changes in the associated technology and the ability of the Company to meet its stated business goals.

Prospective investors should make their own independent evaluation of an investment in the Company or seek advice from their financial adviser, accountant, lawyer, stockbroker or other professional adviser before making any investment decision. Nothing in this presentation should be construed as financial product advice, whether personal or general, for the purposes of Section 766B of the Corporations Act, or otherwise. This presentation does not amount to, involve or imply a recommendation or a statement of opinion in respect of whether to buy, sell or hold a financial product.

Neither Hydrix nor any of its or their associates or any of the Company’s directors’ (Hydrix Group) shall have any liability whatsoever for: (a) investment advice; (b) a recommendation to enter into any transaction or strategy; (c) advice that a transaction or strategy is suitable or appropriate; (d) the primary basis for any investment decision; (e) a representation, warranty, guarantee with respect to the legal, accounting, tax or other implications of any transaction or strategy; or (f) to cause the Hydrix Group to be an advisor or fiduciary of any recipient of this report or other third party. None of the Hydrix Group shall be responsible for or have any liability to you for losses or damages (whether consequential, incidental or otherwise) arising in any way for errors or omissions in, or the use of or reliance upon the information contained in this document. To the greatest extent permitted by law, we exclude all conditions and warranties that might otherwise be implied by law with respect to the document, whether by operation of law, statute or otherwise, including as to their accuracy, completeness or fitness for purpose. Unauthorised copying of this document is prohibited.

